F-star, a biopharmaceutical company developing immunooncology bispecific antibodies, has opened a new facility in the Eddeva building on the Babraham Research Campus in Cambridge, UK. The company also announced the appointment of Michael Davies as vice president of protein sciences.

The new facility will house F-star's expanded team which has grown to just over 60 members of staff over the last year. F-star has successfully hired several key employees and developed its modular antibody technology for the discovery of bispecific antibody therapeutics.

In January 2016, F-star announced a collaborative discovery & development agreement with AbbVie for the development of bispecific antibodies against two immuno-oncology targets. The company also has partnerships with Bristol-Myers Squibb, Merck Serono, and Boehringer Ingelheim.

Mike Davies joins F-star as VP Protein Sciences from CPI Biologics where he worked as head of analytical strategy, biologics. He has over 15 years' experience in the development, manufacture and commercialization of recombinant protein therapeutics. He has successfully run chemistry, manufacturing and control (CMC) projects to support the launch of several commercial products. Previously, he worked at Lonza, where he held leadership roles in analytical strategy and development.

Source: F-Star